



#### Disclaimer

This document contains certain forward-looking statements concerning Danone. Although Danone believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties, please refer to the section "Risk Factors" in Danone's Annual Report (which is available on <a href="www.danone.com">www.danone.com</a>). Danone undertakes no obligation to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy, Danone shares.



#### **KEY FIGURES - H1 10**

Sales	$\Longrightarrow$	€ 8,364 mln	+7.0% like-for-like (1) +11.2% reported
Trading operating income	$\Longrightarrow$	€ 1,280 mln	+2.0% like-for-like (1) +6.1% reported
Trading operating margin	$\Longrightarrow$	15.30%	(74) bps like-for-like (1) (73) bps reported
			, , , -
Underlying net income from continuing activities		€ 848 mln	+10.1% like-for-like (1,2) +17.5% reported
			•
Underlying EPS (fully diluted)			. 7 70/ like for like (12)
from continuing activities		€ 1.38	+7.7% like-for-like (1,2) (7.9)% reported
Free cash flow (3)	$\Longrightarrow$	€ 858 mln	+ 34.9% reported


<sup>(1)</sup> At constant scope of consolidation and constant exchange rates

<sup>(2)</sup> Excluding exceptionals and excluding the effects of the capital increase

<sup>(3)</sup> Free Cash Flow: Cash flow from operations less capital expenditure (net of disposals)




#### Sales growth analysis - H1 10



H1 2009 H1 2010



#### Sales growth analysis - Q2 10



Q2 2009 Q2 2010



# Sales performance by division



#### FRESH DAIRY - Continued strong momentum



- Virtually all countries deliver positive volume growth
- "Reset" countries deliver sustained volume and sales momentum
- Particular strong growth momentum coming from the US, Brazil, Mexico, Argentina and Japan




# FRESH DAIRY - Volume performance remains strong while value growth trends up

#### Like-for-like growth





#### FRESH DAIRY - Volumes & Price/kg per quarter






### FRESH DAIRY - Volumes & Price/kg per quarter USA





#### FRESH DAIRY - Sales growth is geographically broad-based





#### **FRESH DAIRY- Selected innovations**



Griego Fruta Cortada Spain, Portugal



Vitalinea Stevia France



Danonino Ice Spain & Portugal



Brazil



Danonino Family Pack Brazil




Ser Calci+ Argentina





#### WATERS - Best sales growth performance since Q1 08




- Improving, volume-driven, growth partly offset by negative country mix
- Continued, broad-based, mid-teens growth in developing countries
- 3<sup>rd</sup> consecutive quarter of underlying improving trend in industrialized markets



### WATERS - Sales France & Germany

#### Like-for-like sales growth





#### **WATERS - Selected innovations**





Volvic 3 Ltr France




Bonafont Mineralizada Mexico



Evian Live Young Campaign Worldwide



#### **BABY NUTRITION - Continued strong performance**



- Resilient high single-digit performance driven by volumes (+8.4%)
- Milk portfolio continues to drive the growth while weaning food category stabilizes
- Most markets continue to show market share gains, most notably the UK, Argentina, Brazil, France and Turkey



#### **BABY NUTRITION - Selected innovations**



Pregnancy & Lactation products France & Ireland



**Olvarit Fruit Premium Cups** The Netherlands



Mein MiluMenü Austria



Mellin & Milupa 1.2 Kg packs Italy



Blédina plates France




milupa

Mein MiluMenü

**Pregnancy Supplements** France



# MEDICAL NUTRITION - Broad-based double-digit performance



- Strong double-digit sales growth, driven by volumes (+10.5%)
- Performance continues to be broad-based across regions and across product groups
- Pediatrics and the gastro intestinal allergy product range continue to outgrow the divisional average



#### **MEDICAL NUTRITION - Selected innovations**



Nutilis Aqua 3 flavors: orange, grenadine, mint



Milupa Fruta Protein ready to drink







Nutilis Complete, swallowing issues 3 flavors: vanilla, strawberry, chocolate




KetoCal - Epilepsy USA



Nutrison Advanced Protison for increased protein requirements



### Broad-based geographic growth






### Trading operating income and margin

€ mln	H1 2009	H1 2010
Trading operating income	1,206	1,280
Other operating items	205	(17)
Operating income	1,411	1,263
Trading operating margin	16.03%	15.30%




### Stable margin compared to FY 2009

#### Reported margins





# Stable margin compared to FY 09 despite raw material headwind




H1 2009

H1 2010



#### Danone's milk cost inflation expected to be around 10%

Development of worldwide SMP price, January 2006 to July 2010, (USD/kg indexed) Development of average farm gate price, January 2007 to June 2010, (price/ton indexed)





# Cost saving initiatives well on track to deliver approx € 500 mln of savings by year-end

- € 230 mln of cost savings achieved in H1 10
- Well on track to achieve full-year target of approximately € 500 mln
- Examples of efficiency initiatives:





# Trading operating margin by business line & geographical area

	Repo	Reported		
	H1 2009	H1 2010	Like-for-like change	
Fresh Dairy	15.07%	13.94%	(94) bps	
Waters	14.01%	13.70%	(75) bps	
Baby Nutrition	19.11%	19.19%	(27) bps	
Medical Nutrition	21.24%	19.90%	(86) bps	
Europe	16.74%	16.26%	(44) bps	
Asia	18.83%	19.54%	+12 bps	
Rest of World	13.18%	11.55%	(155) bps	
Total	16.03%	15.30%	(74) bps	



### From operating income to net income

€ mln	H1 2009	H1 2010	Non current items	H1 2010 Underlying
Trading operating income	1,206	1,280	-	1,280
Other operating items	205	(17)	(17)	-
Operating income	1,411	1,263	(17)	1,280
Total financial expenses	(205)	(118)	(5)	(113)
Income tax	(228)	(275)	5	(280)
Net income of affiliates	30	51	7	44
Net income of discon.activities	0	-	-	-
Net income	1,008	921	(10)	931
Attributable to minority interests	76	83	-	83
Attributable to the parent	932	838	(10)	848




#### Tax rate evolution

€ mln	H1 2009	H1 2010
Total income tax (reported)  Reported tax rate  Non current income tax	(228) 18.9% (8)	(275) 23.99% 5
Current income tax	(220)	(280)
Underlying tax rate	22.5%	23.99%




#### Underlying EPS from continuing activities





#### Analysis of fully diluted EPS growth H1 10



<sup>(1)</sup> On a fully diluted basis



### Free cash flow from operations

€ mln	H1 2009	H1 2010
Cash flow from operating activities	846	1,185
Net change in working capital	(13)	(68)
Capital expenditure	(305)	(275)
as a % of sales	4.1%	3.3%
Asset sales	108	16
Free cash flow from operations (1)	636	858 + 34.9%
as a % of sales	8.5%	10.3%

<sup>(1)</sup> Free Cash Flow: Cash flow from operations less capital expenditure (net of disposals)

<sup>\*</sup> A detailed cash flow overview can be found in the appendix



#### Synthetic Balance Sheet



<sup>(1)</sup> Excluding cash & cash equivalents and marketable securities

<sup>(2)</sup> Net of cash & cash equivalents and marketable securities

Derivative instruments with a positive fair value are now presented in a specific line on the asset side of the balance sheet and are no longer netted with non-current financial liabilities



# OUTLOOK



#### Outlook 2010

**Objectives 2010** Sales growth<sup>1</sup> At least +6% EBIT margin <sup>1</sup> Stable margin Free cash flow At least +10%

<sup>&</sup>lt;sup>1</sup> Based on constant scope of consolidation and constant exchange rates

# **APPENDIX**



## Impact of currency and scope - Q2 10

	Dairy	Waters	Baby Nutrition	Medical Nutrition	Group
Reported sales growth	+13.8%	+12.5%	+15.7%	+16.0%	+14.0%
Currency	+6.9%	+7.5%	+7.7%	+4.8%	+7.0%
Scope of consolidation	+0.3%	+0.2%	(0.7)%	+0.4%	+0.1%
Like-for-like sales growth	+6.6%	+4.8%	+8.7%	+10.8%	+6.9%



# Impact of currency and scope - H1 10

	Dairy	Waters	Baby Nutrition	Medical Nutrition	Group
Reported sales growth	+11.6%	+7.3%	+13.0%	+13.9%	+11.2%
Currency	+4.4%	+5.3%	+5.2%	+3.6%	+4.7%
Scope of consolidation	+0.1%	(1.7)%	(0.8)%	+0.2%	(0.5)%
Like-for-like sales growth	+7.1%	+3.7%	+8.6%	+10.1%	+7.0%



# Q2 2010 sales by business & geographical area

€ mln	Q2 2009	Q2 2010	Like-for-like sales growth
Fresh Dairy Products	2,141	2,436	+6.6%
Waters	735	828	+4.8%
Baby Nutrition	741	857	+8.7%
Medical Nutrition	229	265	+10.8%
Europe	2,327	2,420	+1.4%
Asia	479	635	+15.3%
Rest of World	1,040	1,331	+15.9%
GROUP	3,846	4,386	+6.9%



# Q2 2010 like-for-like sales growth Breakdown volume/value

Like-for-like	Volume	Value	Total
Fresh Dairy Products	+9.3%	(2.7)%	+6.6%
Waters	+7.8%	(3.0)%	+4.8%
Baby Nutrition	+8.4%	+0.3%	+8.7%
Medical Nutrition	+10.5%	+0.3%	+10.8%
Europe	+5.1%	(3.7)%	+1.4%
Asia	+13.6%	+1.7%	+15.3%
Rest of World	+13.0%	+2.9%	+15.9%
GROUP	+8.9%	(2.0)%	+6.9%



# H1 2010 sales by business & geographical area

€ mln	H1 2009	H1 2010	Like-for-like sales growth
Fresh Dairy Products	4,262	4,755	+7.1%
Waters	1,349	1,448	+3.7%
Baby Nutrition	1,464	1,654	+8.6%
Medical Nutrition	445	507	+10.1%
Europe	4,517	4,695	+1.7%
Asia	950	1,162	+13.8%
Rest of World	2,053	2,507	+16.0%
GROUP	7,520	8,364	+7.0%



# H1 2010 like-for-like sales growth Breakdown volume/value

Like-for-like	Volume	Value	Total
Fresh Dairy Products	+10.9%	(3.8)%	+7.1%
Waters	+8.1%	(4.4)%	+3.7%
Baby Nutrition	+8.6%	0.0%	+8.6%
Medical Nutrition	+9.4%	+0.7%	+10.1%
Europe	+5.8%	(4.1)%	+1.7%
Asia	+14.3%	(0.5)%	+13.8%
Rest of World	+14.6%	+1.4%	+16.0%
GROUP	+9.8%	(2.8)%	+7.0%



### Cash flow statement

€ mln	H1 2009	H1 2010
Operating income	1,206	1,280
Financial income	(226)	(113)
Income tax	(220)	(280)
Non-current income	218	(17)
Depreciation and amortization	260	285
Net change in provisions	30	41
Dividends received from equity-accounted affiliates	58	9
Other cash items	(141)	(73)
Other non-cash items	(339)	53
Cash flow provided by operating activities, excluding changes in net working capital	846	1,185



### Cash flow statement

€ mln	H1 2009	H1 2010
Cash flow provided by operating activities, excluding changes in net working capital	846	1,185
Change in working capital	(13)	(68)
Cash flow from operations	833	1,117
Capital expenditure	(305)	(275)
Business combinations and other investments, net of cash and cash equivalents acquired	(26)	(37)
Proceeds from the sale of businesses and other assets	811	18
Change in long-term loans and other long-term assets	12	3
Cash flow used in investing activities and disposals	492	(291)




#### Cash flow statement

€ mln	H1 2009	H1 2010
Increase in capital and additional paid-in-capital	2,980	35
Purchases of treasury stock (net of disposal)	75	33
Dividends paid to Danone shareholders	(221)	(737)
Transactions with non-controlling interests*	(54)	(93)
Settlement of debt hedge financial instruments	-	(8)
Change in bonds	-	0
Change in non-current financial liabilities	(3,100)	98
Change in current financial liabilities	(95)	89
Change in marketable securities	(871)	(147)
Cash flow used in financing activities	(1,286)	(730)
Exchange rate differences	(13)	101
Increase (decrease) in cash and cash equivalents	26	197

\* Including dividends



#### Debt maturity profile



**CP** 

Put

options



# Changes in exchange rates 39% of sales denominated in €

	H1 10 % total sales	H1 10 vs H1 09 (avg)	Q2 10 vs Q2 09 (avg)
US Dollar	9%	0%	+8%
Mexican Peso	6%	+10%	+14%
British Pound	5%	+3%	+4%
Chinese Yuan	5%	0%	+8%
Indonesian Rupee	5%	+21%	+25%
Argentinean Peso	4%	(6)%	+3%
Russian Ruble	4%	+10%	+14%
Polish Zloty	4%	+12%	+10%
Brazilian Real	4%	+23%	+26%
Canadian Dollar	2%	+17%	+22%
Turkish Lira	2%	+6%	+10%







